Quanterix Corporation (QTRX)

Over the past six months, Quanterix Corp. stock has experienced fluctuations, with a price of $5.75 as of October 22, 2025, a 53.18% decline from the previous year. Key events include a Q2 2025 earnings report with an EPS miss of -$0.77 and revenue below estimates, though the stock rose after the Q4 2024 announcement. Analyst ratings in September and October 2025 were a consensus "Hold," with Weiss Ratings reiterating a "Sell" rating. There have been insider purchases, and institutional investors have adjusted their stakes. Quanterix completed the Akoya acquisition, expected to expand its biomarker reach, and Leerink noted a "meaningful positive" due to the CMS fee schedule.

The provided search results do not contain explicit information regarding the demand seasonality for Quanterix Corp.'s products and services. Demand might be relatively stable throughout the year, driven by ongoing research initiatives, clinical trials, and healthcare needs rather than strong seasonal fluctuations. Broader economic or industry-specific funding cycles might influence demand more than traditional seasonality.

Quanterix Corporation, established in 2007 and headquartered in Billerica, Massachusetts, is a life sciences company focused on digitizing biomarker analysis to advance precision health. The company's core technology, Simoa, enables the detection of biomarkers at levels previously undetectable, crucial for early disease detection, personalized medicine, and drug development. Quanterix offers Simoa technology, Simoa assay kits, instruments like the HD-X Analyzer™ and SR-X™ Biomarker Detection System, the Simoa Accelerator Laboratory, Uman NF-Light™, custom assay development services, and consumables. Its technology is used in research across neurology, oncology, immunology/inflammation, infectious disease, and cardiology.

Quanterix Corporation is headquartered in Billerica, Massachusetts, and operates in North America, EMEA, and Asia Pacific. The HD-X Simoa Immunoassay Analyzer received Class 1 Medical Device registration in South Korea in June 2025. The Quanterix Accelerator Laboratory was also awarded a New York State Clinical Laboratory Permit in August 2025.

Quanterix's brand reputation is influenced by its technological advancements, strategic business moves, and financial performance. The company is recognized for its Simoa technology. The Akoya acquisition and expansion into global markets positively contribute to its reputation. The planned launch of the next-generation Simoa One platform is anticipated to expand its market. Recent quarterly earnings showed a revenue decline and an EPS miss, which could temporarily impact investor sentiment. News headlines indicate a mix of positive and negative sentiment.

Quanterix Corporation's ownership is distributed among institutional investors, individual shareholders, and company insiders, with institutional investors holding 68.4% of the stock as of recent data. As of October 22, 2025, there were 291 institutional owners holding a total of 41,422,563 shares. Major institutional owners include BlackRock Fund Advisors, The Vanguard Group, and Ameriprise Financial Inc.